Arthur D. Little, Inc.

Acorn Park
Cambridge, Massachusetts 02140-2390
617 864-5770 Telex 921436

June 9, 1986

1986
At the frontier
1886

Dr. John E. Glenn
Nuclear Regulatory Commission
Chief, Nuclear Materials Safety Section B
Division of Radiation and Safeguards
Region I
631 Park Avenue
King of Prussia, PA 19406

Dear Dr. Glenn:

We are herewith requesting an amendment to our U.S. Nuclear Regulatory Commission License No. 20-01489-01. One part of the proposed amendment is to designate Ms. Madeline F. McComish to replace Dr. Richard F. Taylor as a member of the Radiation Safety Committee and as Deputy Radiation Safety Officer. A biography of Ms. McComish's is attached (Attachment 1).

A second part of the amendment is a change in Item 6 through 8 to permit us to transfer two small irradiators from existing NRC License 20-01489-05 to License 20-01489-01. Following the proposed transfer, the 20-01489-05 license would be terminated.

The amendment fee of $120 is enclosed. Attached are the specific items of the amendment allowing the transfer of material to License No. 20-01489-01 (Attachment 2).

Very truly yours,

Emmett M. Smith

Emmett M. Smith
Radiation Safety Officer

/laf
enclosure
attachments

ATTACHMENT 1

MADELINE MCCOMISH, M.S.

Ms. Madeline McComish is a member of the Biomedical Research and Technology Section of Arthur D. Little, Inc. She is a specialist in the "hands on" development, validation and performance of high performance liquid chromatographic assays in support of xenobiotic metabolism and toxicology studies. She has either developed or validated our in-house HPLC methods for nucleotides and deoxynucleotides and for many other compounds, including dyes and pigments, dansyl and ortho-phthalaldehyde amino acid derivatives, experimental antitumor and steroidal agents, corticosterone, prednisolone, and diethylhexylphthalate (DEHP) metabolites in the urine and feces of monkeys, rats and mice. She is also responsible for determining by HPLC assays the purity, concentration and homogeneity of dosing formulations used in animal studies as well as the purity of radiolabeled compounds. She is familiar with automated data reduction systems and the statistical analysis of data. Ms. McComish is involved in the design of these studies, in the implementation of Good Laboratory Practices (GLP), and in the writing of draft and final reports to clients.

Ms. McComish has extensive experience in the isolation of metabolites from biological samples by normal and reverse phase preparative HPLC. Examples include the isolation of the urinary metabolites of DEHP, a new caffeine metabolite and the degradation products of an experimental antitumor agent. Thin-layer chromatographic, polarographic and high-voltage electrophoretic techniques have also been used by her for the analysis of xenobiotics and metabolites in biological samples.

Other projects include: the evaluation of a new line of reverse phase and ion-exchange HPLC columns by comparing their performances with those of commercially available columns; the assessment of technical data relating to mammalian toxicity and human health effects associated with exposure to environmental pollutants; and a review of analytical data used to support a New Drug Application.

From 1969 to 1976 Ms. McComish was positioned in the Clinical Chemistry Laboratory of Arthur D. Little, Inc., and from 1972 to 1976 she headed this laboratory. She was responsible for both clinical and research analyses and maintenance and operator instruction for a twelve channel Technicon and other auto analyzers. Her responsibilities included the design and implementation of new protocols.

Ms. McComish received her A.B. in Chemistry from Regis College and a M.S. in Chemistry from Northeastern University in 1980. She has completed the Waters Associates courses in analytical and preparative liquid chromatography and she is a member of the American Chemical Society. She is the co-author of more than fifteen scientific publications and is the Chairman of the Section Safety Committee.

ATTACHMENT 2

Amendment to Items 6, 7 and 8 of License 20-01489-01.

6. Byproduct, source and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may pocess at any one time under license
I. Cesium 137	Sealed Source (J.L. Shepherd and Association Model 6810)	3237 Ci (originally 4000 Ci 4/1/77)
J. Cobalt 60	Sealed Source (Tech Ops, Inc. Model 624)	222 Ci (originally 3000 Ci 8/22/66)

The irradiators will still be maintained at our 38 Memorial Drive, Cambridge, Masschusetts, facility under the present conditions, i.e., the Cobalt 60 irradiator is in a storage mode and the Cesium 137 irradiator is in an active usage mode.